Inactive Instrument

Albireo Pharma, Inc. Stock price

Equities

ALBO

US01345P1066

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 15-05-31
Founder 60 03-12-07
President 57 23-03-01
Members of the board TitleAgeSince
Director/Board Member 54 23-03-01
Director/Board Member 61 23-03-01
Chief Executive Officer 61 15-05-31
More insiders
Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
More about the company
  1. Stock
  2. Equities
  3. Stock Albireo Pharma, Inc. - Nasdaq